Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

NCT03595592 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT03595592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)
Lead sponsor
Fondazione Michelangelo
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 7, 2018
Completion date
March 15, 2027
Enrollment
650 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast cancer